awmsg logo



levodopa-carbidopa intestinal gel (Duodopa®)


Reference No. 3397


Appraisal information

levodopa-carbidopa intestinal gel (Duodopa®) 20 mg/ml + 5 mg/ml intestinal gel


Company: AbbVie Ltd
BNF category: Central nervous system
NMG meeting date: 04/10/2017
AWMSG meeting date: 08/11/2017
   
   
Submission Type: Resubmission
Status: In progress
Advice No: Not available
Ministerial ratification: Not available

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

Indication

Treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results
Preliminary Appraisal Recommendation (PAR)
Download
Company Response to the Preliminary Appraisal Recommendation (CR PAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download